Viking Therapeutics announced on March 26, 2025, the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of VK2735. This VENTURE-Oral Dosing Trial is designed to evaluate the safety, tolerability, pharmacokinetics, and weight loss efficacy of VK2735 dosed once daily for 13 weeks in patients with obesity.
The study successfully enrolled approximately 280 adults who are obese or overweight with at least one weight-related co-morbid condition. The rapid enrollment rate highlights the continued enthusiasm for new obesity therapeutics like VK2735 among investigators and study subjects. This efficient enrollment keeps the program on schedule.
Viking expects to report top-line data from this Phase 2 study in the second half of 2025. The completion of enrollment is a significant operational milestone, moving the oral VK2735 program closer to a critical data readout that will inform its future development path and competitive positioning in the oral weight-loss market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.